^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CYTO NK-102
i
Other names: CYTO NK-102, CYTO-102, COH06
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
City of Hope, CytoImmune
Drug class:
NK cell stimulant
Related drugs:
6ms
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors (clinicaltrials.gov)
P1, N=6, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2025 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Jun 2026
Trial completion date • Trial primary completion date • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • CYTO NK-102
over1year
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors (clinicaltrials.gov)
P1, N=6, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=21 --> 6
Enrollment closed • Enrollment change • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • CYTO NK-102
over2years
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors (clinicaltrials.gov)
P1, N=21, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2025 --> Sep 2025 | Trial primary completion date: Jan 2025 --> Sep 2025
Trial completion date • Trial primary completion date • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • CYTO NK-102
Share via
